Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from ...

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business strategy.

Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Myocarditis is a known — but small — side effect of the mRNA Covid vaccines from Pfizer and Moderna, information that federal ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.